- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02127437
Lanreotide In Polycystic Kidney Disease Study (LIPS)
LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to start in early 2014.
An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to 60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30 ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by repeated measures, in the overall population as well as in the two GFR stratus.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Necker Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- autosomal dominant polycystic kidney disease (clinical, familial, imaging grounds)
- measured GFR : 30 to 89 ml/mn/1.73m2
- age > 18
- affiliated with health insurance
- written informed consent
Exclusion Criteria:
- iohexol /iodine allergy
- diabetes mellitus
- other associated nephropathy suspected
- evolutive or recent malignant disease ( in the previous 5 years)
- cholelithiasis
- uncontrolled hypertension (BP>160/100 mmHg)
- cardiac failure of grade III or IV according to the NYHA (New York Heart Association) classification
- liver failure
- psychiatric illness
- pregnancy, lactation, lack of contraception
- use of somatostatin analogs during the last 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A - treated group
|
120 mg, subcutaneously, once every 4 weeks
|
Placebo Comparator: B - control group
|
0,5 ml, subcutaneously, once every 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glomerular filtration rate (GFR)
Time Frame: month 36
|
month 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glomerular filtration rate (GFR)
Time Frame: month 18
|
month 18
|
|
Glomerular filtration rate (GFR) decline
Time Frame: month 36
|
month 36
|
|
Safety, tolerance
Time Frame: month 36
|
month 36
|
|
Onset or worsening of hypertension
Time Frame: month 18
|
month 18
|
|
Onset or worsening of hypertension
Time Frame: month 36
|
month 36
|
|
Quality of life
Time Frame: month 0
|
SF-36, EQ5D
|
month 0
|
Quality of life
Time Frame: month 18
|
SF-36, EQ5D
|
month 18
|
Quality of life
Time Frame: month 36
|
SF-36, EQ5D
|
month 36
|
Cystic pain
Time Frame: month 36
|
month 36
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dominique JOLY, MD, PhD, Necker Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LIPS-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autosomal Dominant Polycystic Kidney Disease (ADPKD
-
University of North Carolina, Chapel HillNational Institute of General Medical Sciences (NIGMS)CompletedRenal Disease | Autosomal Dominant Polycystic Kidney Disease | ADPKDUnited States
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
University Medical Center GroningenRadboud University Medical Center; Erasmus Medical Center; Leiden University...UnknownAutosomal Dominant Polycystic Kidney Disease (ADPKD)Netherlands
-
Mario Negri Institute for Pharmacological ResearchCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Italy
-
Palladio BiosciencesCentessa Pharmaceuticals plcTerminatedADPKD | Polycystic Kidney Disease, AdultUnited States
-
Children's National Research InstituteRecruiting
-
Tufts Medical CenterCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Vertex Pharmaceuticals IncorporatedNot yet recruitingAutosomal Dominant Polycystic Kidney Disease (ADPKD)
-
University of CologneRecruitingADPKD (Autosomal Dominant Polycystic Kidney Disease)Germany
-
University of ZurichCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Switzerland
Clinical Trials on Lanreotide
-
University Hospital, GhentCompleted
-
IpsenCompleted
-
IpsenCompletedCarcinoma | Peritoneal Neoplasms | Intestinal ObstructionFrance, Netherlands, Belgium
-
Radboud University Medical CenterIpsenUnknownLiver Diseases | Hepatomegaly | Polycystic Liver Disease | Polycystic Kidney | Autosomal DominantNetherlands, Belgium
-
IpsenCompleted
-
Asan Medical CenterSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsRecruitingNeuroendocrine TumorsKorea, Republic of
-
Federation Francophone de Cancerologie DigestiveTerminatedMetastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine TumoursFrance, Belgium, Germany, United Kingdom
-
University Hospital, GhentIpsenCompleted
-
IpsenCompletedGastroenteropancreatic Neuroendocrine TumorChina
-
IpsenCompletedAcromegalyFrance, Switzerland